The Imaging Group (IG) operates to establish and maintain the scientific and clinical value of advanced imaging.
Optimal image quality is essential for imaging implementation in clinical trials. A European accreditation system to implement the EANM (European Association of Nuclear Medicine) guideline and the quality control (QC) procedures was set up and is run under the direction of EARL (EANM Research Ltd.) and the EORTC.
The IG plays a central role in the conduct of the Innovative Medicines Iniatiative QuIC-ConCePT project which aims to qualify imaging biomarkers of tumor cell proliferation, apoptosis, and necrosis allowing drug developers to reliably demonstrate the modulation of these pathologic processes in patients with malignant tumors in clinical trials. Initial work includes a quality assurance exercise for diffusion-weighted MRI and [18F]-3′-fluoro-3′-deoxy-L-thymidine (FLT) PET. Appropriate phantoms for measurement of system stability and test-retest imaging methods have been developed, and the technical validation clinical studies are now being run to assess the reproducibility of imaging biomarkers. A standardization procedure of diffusion MRI is being established with collaboration between QuIC-ConCePT in Europe and quantitative imaging biomarker association (QIBA) in the United States.
RECIST equivalent for bone metastases
The IG has established a committee whose aim is to achieve guidelines for imaging bone and to create some sort of RECIST equivalent for the assessment of bone metastases that can be used in cancer clinical trials. This committee is composed of specialists in both radiology and nuclear medicine and met for the first time in September 2012 to review the current state of the art, discuss the limitations and pitfalls, and devise a strategic plan.